The FDA recently approved monoclonal antibody drugs like Donanemab for Alzheimer’s treatment. These drugs target amyloid plaques in the brain, believed to be linked to cognitive decline. Clinical trials show a delay in cognitive decline, but also risk of brain bleeding and swelling. Donanemab appears to be most effective, while Aducanumab has been discontinued. Patients with genetic risk factors for Alzheimer’s or previous cardiovascular issues may be more prone to complications. Treatment with monoclonal antibodies requires careful monitoring and individualized plans. The amyloid plaque hypothesis is being questioned in Alzheimer’s research, as scientists continue to search for effective treatments.
Source link
What’s The Deal With Monoclonal Antibody Therapies for Alzheimer’s?
